A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 50/6 NEXT DPI (FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE 50 µg PLUS FORMOTEROL FUMARATE 6 µg ) VERSUS THE FREE COMBINATION OF LICENSED BECLOMETASONE DPI AND FORMOTEROL DPI IN ASTHMATIC CHILDREN

Trial Profile

A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 50/6 NEXT DPI (FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE 50 µg PLUS FORMOTEROL FUMARATE 6 µg ) VERSUS THE FREE COMBINATION OF LICENSED BECLOMETASONE DPI AND FORMOTEROL DPI IN ASTHMATIC CHILDREN

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Beclometasone; Formoterol
  • Indications Asthma
  • Focus Pharmacokinetics
  • Acronyms PAED4
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Nov 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01468272).
    • 15 Nov 2011 Planned End Date (1 Aug 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top